Jubilant Pharmova reported a more than two-fold increase in consolidated profit after tax, reaching Rs 61 crore for Q4 2024. The company's total income from operations stood at Rs 1,773 crore. For the full fiscal year, net profit surged to Rs 195 crore, with significant growth plans announced for international and US markets.
Jubilant Pharmova posts Q1 net profit of Rs 160 crore
The company had posted a net profit of Rs 35.39 crore for the year-ago period, Jubilant Pharmova said in a regulatory filing With a gradual recovery in nuclear medicine procedures, the turnaround plan of radio pharmacy business is on track (Source: PTI) PTI
Updated Jul 24, 2021, 9:13 AM IST
Drug firm Jubilant Pharmova on Friday reported a consolidated net profit of Rs 160.49 crore from continuing operations for the quarter ended June 30, 2021. The company had posted a net profit of Rs 35.39 crore for the year-ago period, Jubilant Pharmova said in a regulatory filing.
Revenue from continuing operations stood at Rs 1,634.65 crore in the quarter under review. It was Rs 1,156.07 crore in the same period a year ago, it added.
Jubilant Pharmova posts Q1 consolidated net profit of Rs 160 crore business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
Jubilant Pharmova arm completes studies using novel oral formulation of Remdesivir
216
NEW DELHI, April 19, 2021 (BSS/PTI) – Jubilant Pharmova on Monday said its arm Jubilant Pharma has successfully completed studies using a novel oral formulation of Remdesivir used for treatment of COVID-19 against the available injectable formulation of the antiviral drug in India.
Jubilant Pharma has successfully completed “safety and pharmacokinetic/absorption studies in animals and healthy human volunteers in India using a novel oral formulation of Remdesivir against the commercially available injectable formulation of Remdesivir,” Jubilant Pharmova said in a filing to BSE.
Jubilant has sought authorisation for additional studies for this novel oral formulation from the Drug Controller General of India (DCGI), it added.